(R)-RP-6306（Cat No.:I043442）is a selective small molecule inhibitor designed to target the receptor tyrosine kinase AXL, which is involved in regulating cell survival, migration, and immune evasion. AXL is often overexpressed in various cancers, contributing to tumor progression, metastasis, and resistance to therapies. By inhibiting AXL, (R)-RP-6306 aims to disrupt these oncogenic processes, potentially sensitizing tumors to conventional treatments and improving patient outcomes. This compound is being studied for its potential therapeutic applications in cancer therapy, particularly in cancers where AXL plays a key role in disease progression and drug resistance.